The present invention discloses non peptide prokineticin 1 receptor agonists and their uses for the treatment of PKRl mediated disorders, in particular for the treatment of vascular diseases, neurodegenerative diseases, diseases involving impaired gastrointestinal motility, obesity, Kallmann syndrome, normosmic hypogonadotropic hypogonadism and disturbances of circadian rhythm, and to prevent or limit the toxicity, in particular the cardiotoxicity and neurotoxicity, of drugs. The present invention also discloses a prokineticin receptor-1 agonist for use for promoting the differentiation of cardial epicardin+ progenitor cells into cardiomyocytes in a subject affected with a cardiac disease and/or the differentiation of renal epicardin+ progenitor cells into vasculogenic and/or glomerular cells in a subject affected with a renal disease. The present invention further discloses a prokineticin receptor-1 agonist for use for treating or preventing insulin resistance, in particular associated with type II diabetes.
Desaubry, L., Desaubry, G.C., Boulberdaa, M., Kindo, M., Tafi, A., Brogi, S., et al. (2012)Prokineticin 1 receptor agonists and their uses. . Brevetto No. WO/2012/084999.
Prokineticin 1 receptor agonists and their uses
TAFI, ANDREA;BROGI, SIMONE;
2012-01-01
Abstract
The present invention discloses non peptide prokineticin 1 receptor agonists and their uses for the treatment of PKRl mediated disorders, in particular for the treatment of vascular diseases, neurodegenerative diseases, diseases involving impaired gastrointestinal motility, obesity, Kallmann syndrome, normosmic hypogonadotropic hypogonadism and disturbances of circadian rhythm, and to prevent or limit the toxicity, in particular the cardiotoxicity and neurotoxicity, of drugs. The present invention also discloses a prokineticin receptor-1 agonist for use for promoting the differentiation of cardial epicardin+ progenitor cells into cardiomyocytes in a subject affected with a cardiac disease and/or the differentiation of renal epicardin+ progenitor cells into vasculogenic and/or glomerular cells in a subject affected with a renal disease. The present invention further discloses a prokineticin receptor-1 agonist for use for treating or preventing insulin resistance, in particular associated with type II diabetes.
| File | Dimensione | Formato | |
|---|---|---|---|
|
iasr.pdf
non disponibili
Tipologia:
Altro materiale allegato
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
23.3 kB
Formato
Adobe PDF
|
23.3 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/44904
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo